PF-610355
Modify Date: 2025-08-31 18:32:37
PF-610355 structure
|
Common Name | PF-610355 | ||
|---|---|---|---|---|
| CAS Number | 862541-45-5 | Molecular Weight | 617.75500 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C34H39N3O6S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PF-610355PF-610355 is a long-acting inhaled β2-adrenoreceptor agonist, with an EC50 of 0.26 nM. PF-610355 has the potential for the study of asthma and COPD[1]. |
| Name | 2-[3-[2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(methanesulfonamido)phenyl]ethyl]amino]-2-methylpropyl]phenyl]-N-[[3-(4-hydroxyphenyl)phenyl]methyl]acetamide |
|---|---|
| Synonym | More Synonyms |
| Description | PF-610355 is a long-acting inhaled β2-adrenoreceptor agonist, with an EC50 of 0.26 nM. PF-610355 has the potential for the study of asthma and COPD[1]. |
|---|---|
| Related Catalog | |
| In Vivo | PF-610355 is a long-acting (once daily) inhaled β2-adrenoreceptor agonist. PF-610355 has low oral bioavailability due to poor absorption through the gut lumen and high first pass metabolism and warranted further progression. PF-610355 has a short half-life (Clint = 33 (μL/min)/mg) that suggested an unbound intrinsic clearance of >10000 (mL/min)/kg. PF-610355 exhibits an ideal pharmacokinetic profile for an inhaled agent[1]. |
| References |
| Molecular Formula | C34H39N3O6S |
|---|---|
| Molecular Weight | 617.75500 |
| Exact Mass | 617.25600 |
| PSA | 159.86000 |
| LogP | 7.02450 |
| InChIKey | YPHDIMUXXABSSO-YTTGMZPUSA-N |
| SMILES | CC(C)(Cc1cccc(CC(=O)NCc2cccc(-c3ccc(O)cc3)c2)c1)NCC(O)c1ccc(O)c(NS(C)(=O)=O)c1 |
| unii-zh5smu97aj |
| PF-00610355 |